Akeso Inc. (09926) Short-term Analysis: New Drug Clinical Trial Approved, Stock Price Breaks Through HKD 115, Challenging Resistance at HKD 125.2

Entering mid-March, the Hong Kong pharmaceutical sector has shown strong activity, with multiple innovative drug stocks benefiting from industry tailwinds and continuing to rise. As of March 10, 2026, Akeso Inc. (09926) closed at HKD 114.9, surging 10.80%, with a turnover of HKD 1.518 billion, and a 5-day volatility of 18.9%, indicating a robust stock price trend.

In terms of market news, the company’s self-developed globally pioneering tri-specific antibody new drug AK150 (ILT2/ILT4/CSF1R tri-antibody) received an implied approval for clinical trial from the Center for Drug Evaluation of the National Medical Products Administration to conduct clinical trials for the treatment of advanced malignant solid tumors. Public data shows that AK150 is the only tri-specific antibody under research globally targeting ILT2/ILT4/CSF1R, as well as the first tri-antibody drug developed by Akeso Inc. entering the clinical stage, leveraging the company's leading AI-driven drug R&D technology platform and Tetrabody multi-antibody technology platform. In the same sector, pharmaceutical stocks generally rebounded, with CARsgen Therapeutics (02171) rising over 28%, GenFleet Therapeutics (06898) increasing more than 20%, and Biocytogen Pharmaceuticals (02315) showing significant gains, reflecting an evident increase in market attention toward the innovative drug field.

From a technical analysis perspective, Akeso Inc.'s stock price exhibits a strong breakout pattern. According to technical data as of March 10, the stock price at HKD 114.9 has stabilized above the 10-day moving average (HKD 104.19) and the 30-day moving average (HKD 105.8), while just breaking through the 60-day moving average (HKD 112.04), indicating a strengthening short-term trend. The Relative Strength Index (RSI) stands at 55, within the neutral-to-strong region, not yet in overbought territory, implying further upside potential. It is worth noting that several indicators, such as the bull-bear power indicator and Ichimoku Cloud, have issued buy signals, while the Williams %R and Stochastic Oscillator show neutral signals in overbought conditions, and the CCI indicator issues a sell signal in overbought conditions, indicating some divergence among indicators. The overall signal interpretation is 'neutral,' with strength at 9, suggesting the stock may need to consolidate profits before moving upward again in the short term.

In terms of support and resistance levels, the current primary support level is at HKD 104, which is a key short-term defense line. If it breaks below this level, the next critical support area would be at HKD 101.7. On the upside, resistance is concentrated around HKD 125.2 and HKD 128.5, with HKD 125.2 being the short-term breakthrough target. Notably, the smooth progress of the company's clinical trials for its new drug, coupled with favorable industry policies and improved sector sentiment, provides further upward momentum for the stock. Based on the latest stock price at HKD 114.9, which is between the support level of HKD 104 and the resistance level of HKD 125.2, short-term trading should consider following the trend, either waiting for pullbacks to accumulate positions or awaiting breakout signals.

Reviewing the performance of warrant products, three bullish products for Akeso Inc. mentioned on March 6 showed notable performances in the subsequent two days, effectively capturing the underlying stock's rally. Societe Generale bull certificate (61054) recorded a 29% increase over the two days, compared to a 7.27% rise in the underlying stock during the same period; UBS Group bull certificate (64227) $UB#AKESORC2608E.C (64227.HK)$ Recorded a 25% increase; China CITIC Securities call warrant (25534) $BIXIAMI@EC2609A.C (15534.HK)$ Recorded a 22% increase. The gains of all three were much higher than the underlying stock, fully demonstrating the leverage effect of derivatives. In particular, the performance of bull contracts was particularly outstanding, reflecting that products with closer forced recovery prices to the current price are more sensitive to fluctuations in the underlying stock.

In terms of deploying warrant and bull-bear certificate products, investors can choose from the following products based on their own risk preferences, in conjunction with the current support and resistance levels.

Regarding call warrants, Bank of China call warrant (25994) and Societe Generale call warrant (25883) have an exercise price of 131.36 yuan, providing about 3.0 to 3.4 times leverage. This exercise price is associated with key resistance levels of 125.2 yuan and 128.5 yuan, making it suitable for investors who expect the share price to break through resistance and challenge the 130 yuan mark. The advantage of the Bank of China call warrant (25994) lies in its highest leverage (3.4 times) and lower premium, which makes it more attractive to investors seeking amplified returns. Meanwhile, the Societe Generale call warrant (25883) offers the lowest premium and implied volatility, giving it stronger downside protection and controllable time value costs for valuation-sensitive investors.

For put warrants, Huatai put warrant (29749) has an exercise price of 95 yuan, providing approximately 2.1 times leverage. This exercise price correlates with key support levels below 104 yuan and 101.7 yuan, making it suitable for investors expecting the stock price to be constrained by resistance levels and test support levels on a pullback. The Huatai put warrant (29749) stands out due to its highest leverage, making it an option for bearish strategies aiming for amplified effects.

For bull contracts, J.P. Morgan bull contract (61447) $JP#AKESORC2702A.C (61447.HK)$ and HSBC bull contract (61288) both have a forced recovery price of 93 yuan, providing around 3.7 to 3.8 times effective leverage. This forced recovery price is below the primary support level of 104 yuan, offering ample buffer space and making it suitable for investors expecting the stock price to stabilize at the 104 yuan support level and rebound further. The J.P. Morgan bull contract (61447) offers the highest effective leverage at 3.7 times with a lower premium, while the HSBC bull contract (61288) provides the lowest premium and slightly higher effective leverage at 3.8 times, appealing to investors seeking amplified returns and cost control.

For bear contracts, Societe Generale bear contract (55049) $SG#AKESORP2812A.P (55049.HK)$ has a forced recovery price of 134.5 yuan, offering 4.0 times effective leverage; UBS Group bear contract (64129) has a forced recovery price of 133.45 yuan, providing 4.4 times effective leverage. These forced recovery prices correlate with key resistance levels above 125.2 yuan and 128.5 yuan, making them suitable for investors expecting the stock price rebound to be capped by resistance. The Societe Generale bear contract (55049) has the highest effective leverage with a lower premium, while the UBS Group bear contract (64129) offers the lowest premium and higher effective leverage, catering to different risk preferences in bearish strategies.

In summary, investors optimistic about Akeso Inc.'s rebound may consider the Bank of China call warrant (25994) to capture breakout opportunities or the HSBC bull contract (61288) $HS#AKESORC2612B.C (61288.HK)$ for higher leverage deployment. Bearish investors can consider the Huatai put warrant (29749) to hedge downside risks or the UBS Group bear contract (64129) to capture pullback opportunities with the highest leverage.

Interactive Questions:

Dear readers, can Akeso Inc. (09926) successfully break through the resistance level at 125.2 in the short term, benefiting from its new drug’s clinical approval?

A) Yes, the progress of the new drug is positive, and the uptrend is likely to continue.

B) No, it needs to consolidate first within the range of 104 to 125, digesting recent gains.

Feel free to share your thoughts in the comments section!

Reminder: This article does not constitute any investment advice.

This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive assessment of asset performance should combine other data and should not solely rely on this article to make trading decisions. Please note that past performance is not indicative of future results. Follow Jenny's insights on Hong Kong stock warrants for more professional analysis.

$Hang Seng Index (800000.HK)$$Hang Seng TECH Index (800700.HK)$$Hang Seng China Enterprises Index (800100.HK)$

#Kangfang Biotech #09926 #Hong Kong Stocks #Technical Analysis #Support and Resistance Levels #Warrants #Bull and Bear Certificates #Call Options #Put Options #Innovative Drug Sector

52K Views